|
20 Dec 2019 |
European Commission approves Roche’s Kadcyla for the adjuvant treatment of people with HER2-positive early breast cancer with residual invasive disease after neoadjuvant treatment
|
|
20 Dec 2019 |
MacroGenics Announces Submission of Margetuximab Biologics License Application to U.S. FDA
|
|
20 Dec 2019 |
Agenus Commences Combination Trial of its Next-Gen CTLA-4 with its PD-1 Antibody
|
|
20 Dec 2019 |
GSK announces positive headline results in phase 3 study of Benlysta in patients with lupus nephritis
|
|
20 Dec 2019 |
Amgen And Allergan Submit Biologics License Application For ABP 798, Biosimilar Candidate To Rituxan® (rituximab), To U.S. Food And Drug Administration
|
|
20 Dec 2019 |
NeuClone Completes Dosing in Phase I Clinical Trial of Stelara® (ustekinumab) Biosimilar Candidate
|
|
19 Dec 2019 |
FDA Grants Accelerated Approval to Astellas’ and Seattle Genetics’ PADCEV™ (enfortumab vedotin-ejfv) for People with Locally Advanced or Metastatic Urothelial Cancer, the Most Common Type of Bladder Cancer
|
|
19 Dec 2019 |
Daiichi Sankyo Launches Antitumor Agent Bevacizumab Biosimilar for Intravenous Drip Infusions “Daiichi Sankyo” in Japan
|
|
18 Dec 2019 |
OBI Pharma Announces Initiation of a Phase 1/2 Study of Its Antibody-Drug Conjugate (ADC) Targeted Cancer Therapy, OBI-999
|
|
18 Dec 2019 |
BioInvent Has Entered Into a Clinical Trial Collaboration and Supply Agreement to Evaluate BI-1206 in Combination With KEYTRUDA® in Advanced Solid Tumors
|
|
17 Dec 2019 |
Akero Therapeutics Completes Enrollment in Phase 2a Study in NASH
|
|
17 Dec 2019 |
Alligator Bioscience: First Patient Dosed With ATOR-1017 Developed for Metastasized Cancer
|
|
17 Dec 2019 |
ImmunoGen Announces Accelerated Approval Pathway for Mirvetuximab Soravtansine in Ovarian Cancer
|
|
17 Dec 2019 |
Pivotal DREAMM-2 study demonstrated a clinically meaningful overall response rate with belantamab mafodotin (GSK2857916) for patients with relapsed/refractory multiple myeloma
|
|
16 Dec 2019 |
Meiji Seika Pharma and Dong-A Socio Holdings Initiate Phase I Clinical Trial of DMB-3115, a Ustekinumab Biosimilar Candidate
|
|
13 Dec 2019 |
Novartis receives positive CHMP opinion for Beovu® (brolucizumab) for the treatment of wet AMD
|
|
13 Dec 2019 |
Biogen Reports Top-Line Results from Phase 2 Study in Progressive Supranuclear Palsy
|
|
13 Dec 2019 |
CHMP Issues Positive Opinion to Expand CYRAMZA® (ramucirumab) Label to Include Results from RELAY Study in Patients with Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
|
|
13 Dec 2019 |
CHMP Grants Positive Opinion for Expanded Use of Darzalex (daratumumab) in Combination with Bortezomib, Thalidomide and Dexamethasone (VTd) for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible
|
|
13 Dec 2019 |
aTyr Pharma Announces Positive Interim Safety Results from Ongoing Phase 1b/2a Clinical Trial of ATYR1923
|
|
13 Dec 2019 |
Zhejiang Medicine and Ambrx Present Positive Top Line Data from a Phase 1a/1b Clinical Trial of ARX788 in Metastatic HER2 Positive Breast Cancer
|
|
13 Dec 2019 |
Grifols launches XEMBIFY® (immune globulin subcutaneous human-klhw) 20%, a new Primary Immunodeficiency treatment
|
|
13 Dec 2019 |
Silverback Therapeutics Announces Preclinical Data at 2019 San Antonio Breast Cancer Symposium (SABCS) Supporting Development of SBT6050 as a Single Agent and in Combination with Trastuzumab for the Treatment of HER2-Expressing Malignancies
|
|
13 Dec 2019 |
Innate Pharma provides update on lacutamab TELLOMAK trial
|
|
13 Dec 2019 |
Genentech Announces Phase III Study Results for Tecentriq Plus Cotellic and Zelboraf in People With Previously Untreated BRAF V600 Mutation-positive Advanced Melanoma
|
